



LISCure Biosciences Fact Sheet

Company Overview

Core Value

- Single strains of microbes selected for defined pharmacological properties
- Data driven development across oncology, CNS, immunology, and liver diseases
- Goal-oriented integration of R&D and business development expertise

Bacterial Approaches



Fecal Microbiota Transplant



Single strain of naturally food-derived microbiome profiles will most benefit in terms of tolerability and safety. Also, it is much less complicated to assign cause and effect associations with single strains rather than multi strains.

Single strain products are more likely to contain clinical doses than multi-strains due to practical constraint, such as cost and dosage size required.

Although LISCure prioritizes single strain approach with each programs, there are still opportunities to explore multiple strain approaches by mixing-and-matching given that our programs show high potencies in each disease model.

Program Highlights


Our oncology programs including **LB-100** and **LB-200** could suppress the tumor growth significantly in variable types of tumor xenograft models with single administration; **LB-300** showed significant reduction in tumor volume in skin melanoma model.

Our CNS programs, **LB-400** improved motor dysfunction and grip strength in MPTP mice model; **LB-500** reduced motor dysfunction, depressive symptoms, and poor concentration in mice model.


LB-600 improved arthritic symptoms without loss of body weight of CIA mice and showed statistically significant inhibition effects on auto-antibody and inflammatory cytokine level in mice model.

LB-700 and **LB-800** showed significant reduction in body weight and liver weight which will provide benefits in NAFLD and NASH. The program also improved lipid profiles through inhibition of lipogenesis and showed anti-inflammatory/anti-fibrotic effects through suppression of inflammatory/fibrotic gene expression.

Global Facts



The number of microbiome-related papers has increased nearly 100 times in 2016, 85% of which are on human microbiome.



The global market for human microbiome-based drugs should reach a market size of nearly \$9.4 billion by 2024.

Pipeline of Live Biotherapeutic Product Candidates

	Indication	Discovery	In Vitro Validation	In Vivo Efficacy	PK/PD/Tox	IND	Phase 1
Oncology							
LB-100	Colorectal Cancer			Present		2021 1H	2021 2H
	Non-small Cell Lung Cancer (NSCLC)			Present		2021 1H	2021 2H
	Melanoma		Present		2021 1H	2021 2H	
	Solid Tumors		Present		2021 1H	2021 2H	
LB-200	Colorectal Cancer			Present		2021 1H	2021 2H
LB-300	Colorectal Cancer			Present		2021 1H	2021 2H
	Melanoma			Present		2021 1H	2021 2H
	Solid Tumors		Present		2021 1H	2021 2H	
Central Nervous System Disorder							
LB-400	Parkinson's Disease			Present		2021 2H	2022 1H
LB-500	Major Depressive Disorder			Present		2021 2H	2022 1H
Immunology							
LB-600	Rheumatoid Arthritis			Present		2021 2H	2022 1H
Liver Disease							
LB-700	Non-alcoholic Steatohepatitis (NASH)			Present		2022 1H	2022 2H
LB-800	NASH			Present		2022 1H	2022 2H



Contact

Business Development
LISCure Biosciences

626, Gangnam-daero, Gangnam-gu, Seoul, 06035
+82 2 3443 1800 | BD@liscure.bio